WeVote
Log In

Bill

Bill

S 4073

Requires health insurance and Medicaid coverage for testing and treatments to slow progression of Alzheimer's disease and related disorders.

2026-2027 Regular Session Introduced by Tony Bucco and 1 co-sponsor

Requires private insurers and Medicaid to cover Alzheimer’s testing and treatments that slow progression.

Introduced in the Senate, Referred to Senate Commerce Committee
0
WeVote Research Nonpartisan
Bill Summary · S 4073

Summary of Bill S 4073 (New Jersey, 222nd Legislature)

Overview

  • Status: Introduced in the New Jersey Senate and referred to the Senate Commerce Committee on May 4, 2026.
  • Sponsor(s): Primary sponsor (unlisted in the provided text) with co-sponsors: Gordon Johnson and Tony Bucco.
  • Session/Jurisdiction: New Jersey, Senate (Session 222).
  • Title: Requires health insurance and Medicaid coverage for testing and treatments to slow progression of Alzheimer's disease and related disorders.

Purpose and Intent

The bill aims to ensure that individuals diagnosed with Alzheimer's disease and related disorders have access to testing and treatment options designed to slow disease progression. It seeks to mandate coverage by private health insurance plans and public programs (specifically Medicaid) for these services, reducing financial barriers for patients and families and promoting earlier identification and intervention where appropriate.

Key Provisions (as inferred from title and typical scope of such legislation)

Note: The provided summary does not include the full text of the bill. The following outlines reflect common elements in similar coverage-mandating measures and should be confirmed with the full bill text.

  • Coverage Mandate for Testing:

    • Health insurance plans (private/commercial) would be required to cover diagnostic testing for Alzheimer’s disease and related disorders.
    • Criteria for testing (under what indications tests must be covered) would likely align with established clinical guidelines, enabling early and accurate diagnosis.

  • Coverage Mandate for Treatments:

    • Insurance plans would be required to cover therapeutic interventions intended to slow disease progression. This could include:
    • Pharmacologic treatments (e.g., disease-modifying or symptom-relief medications approved by relevant authorities).
    • Non-pharmacologic and supportive therapies included within covered benefits if they are part of approved treatment plans.
    • Coverage would apply to both initial treatment and ongoing management, subject to standard plan cost-sharing structures (deductibles, copays, coinsurance) as allowed by law.

  • Medicaid Coverage:

    • Medicaid program in New Jersey would be required to cover eligible testing and therapeutic interventions for Alzheimer’s disease and related disorders.
    • Provisions to ensure access for Medicaid beneficiaries, potentially including prior authorization standards, formulary considerations, and parity with private coverage where applicable.

  • Non-Discrimination and Parity:

    • Provisions to ensure coverage parity between different types of plans (e.g., no discrimination against individuals based on age, sex, race, or severity of disease in covered services).
    • Rules to prevent waivers that would bypass the mandated coverage.

  • Implementation and Compliance:

    • Timeline for when coverage requirements would take effect (e.g., a phase-in period for insurers).
    • Enforcement mechanisms, remedies for non-compliance, and reporting requirements for health plans and providers.

Affected Parties

  • Private Health Insurance Consumers: Individuals with private health plans would gain mandated coverage for testing and treatments.
  • Medicaid Beneficiaries: Low-income and eligible individuals enrolled in Medicaid would receive mandated coverage for testing and treatments.
  • Healthcare Providers: Providers ordering diagnostic tests or administering treatments could be affected by compliance and documentation requirements.
  • Payers: Private insurers and the state’s Medicaid program would implement coverage changes and monitoring to ensure compliance.

Procedural and Timeline Considerations

  • Committee Action: Referred to the Senate Commerce Committee (as of the introduction date). The committee would review, potentially amend, and advance the bill.
  • Next Steps: If advanced, the bill would move through additional Senate steps (floor vote) and, if passed, to the Assembly and potentially to the Governor for signature or veto. A timeline would depend on committee scheduling and legislative priorities.

Notes and Considerations

  • The bill’s specific definitions (e.g., what constitutes “testing,” which treatments are covered, and any medical necessity criteria) will be critical for implementation.
  • Details on cost implications, funding, and any cost-sharing limits are not provided in the summary and would be important for both insurers and beneficiaries.
  • The presence of co-sponsors suggests bipartisan interest, but the bill’s ultimate content will depend on the text approved by the committee and chamber.

If you’d like, I can incorporate the full bill text (when available) to provide precise language citations and a more detailed provisioning map (e.g., sections, definitions, and effective dates).

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.